The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...

Recent research shows the incredible success of radiofrequency ablation in treating AFib, offering renewed hope for patients.

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the ...

A recent Brazilian study published in Nature Cardiovascular Research has highlighted promising pathways for preventing and ...

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating older patients with atrial fibrillation and heart failure.

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

Sarasota Memorial Hospital has earned the #1 spot among the world's WATCHMAN providers protecting people with atrial ...

Background Differences in the clinical outcomes and level of risk among Asian versus non-Asian patients with atrial fibrillation (AF) have been sparsely investigated.Objective To provide a ...

New e-book explores transformative medtech advancements in pulsed field ablation for atrial fibrillation treatment. LONDON, Feb. 4, 2025 /CNW/ -- Clarivate Plc (NYSE:CLVT) a leadi ...